Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 20% IN WATER vs MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal tubular osmotic pressure, which inhibits water reabsorption and promotes diuresis.
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.
Reduction of intracranial pressure and cerebral edema,Reduction of elevated intraocular pressure,Promotion of diuresis in acute renal failure (as an adjunct),Treatment of dialysis disequilibrium syndrome,Management of oliguric phase of acute renal failure
Reduction of intracranial pressure,Reduction of intraocular pressure,Promotion of diuresis in oliguric acute renal failure (prophylaxis or treatment),Osmotic diuresis for drug overdose (e.g., salicylates, barbiturates),Irrigation solution during transurethral prostatic resection
1-2 g/kg (5-10 m L/kg of 20% solution) intravenously over 30-60 minutes for reduction of intracranial pressure; may repeat every 6-8 hours. For preoperative bowel preparation, 100-200 m L (20% solution) orally.
Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.
0.25–1.5 hours (15–90 minutes) in patients with normal renal function. In oliguric or anuric patients, half-life is markedly prolonged, up to 36 hours, due to reduced clearance.
Terminal elimination half-life of mannitol is approximately 1.5-2 hours in patients with normal renal function. Clinically, duration of osmotic diuresis parallels half-life; in renal impairment, half-life may extend to 24-36 hours, increasing risk of fluid overload and electrolyte disturbances.
Not metabolized; excreted unchanged by the kidneys via glomerular filtration with minimal tubular reabsorption.
Mannitol is not significantly metabolized; it is excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis to pyruvate and lactic acid, and enters the Krebs cycle for energy production.
Primarily renal excretion as unchanged drug. Over 90% of administered dose is excreted unchanged in urine within 24 hours. Less than 5% is metabolized in the liver; negligible biliary/fecal elimination.
Primarily renal excretion: Mannitol is filtered by glomeruli and not reabsorbed, excreted unchanged in urine (approximately 80-90% within 24 hours). Biliary/fecal elimination is negligible (<5%). Dextrose is metabolized to CO2 and water; any excess is excreted renally as glucose if threshold exceeded.
Negligible (<5%); essentially unbound.
Mannitol is not significantly bound to plasma proteins (<1%). Dextrose is not protein bound.
Approximately 0.3–0.6 L/kg. Mannitol distributes primarily in extracellular fluid; does not cross cell membranes readily unless administered in large doses or under pathological conditions (e.g., disrupted blood-brain barrier). Increased Vd may indicate expanded extracellular volume.
Approximately 0.5-0.6 L/kg. Mannitol distributes primarily in extracellular fluid (ECF); it does not enter cells significantly. Clinically, this low Vd indicates confinement to ECF, important for osmotic effects.
Intravenous: 100%. Oral: Not applicable; not administered orally due to poor absorption and osmotic diarrhea. Other routes (e.g., subcutaneous or intramuscular) are not clinically relevant.
Intravenous: 100% bioavailability. Oral bioavailability is negligible (<10%) as mannitol is poorly absorbed and acts as an osmotic laxative; Dextrose is well absorbed orally (100%) but not relevant for this IV formulation.
Contraindicated in anuria or severe renal impairment (Cr Cl < 30 m L/min). Use with caution if Cr Cl < 50 m L/min; monitor serum osmolality and urine output. No specific dose adjustment guidelines exist; consider alternative therapy.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, use with caution and monitor serum osmolality; reduce dose or extend interval. No specific dose reduction formula established.
No specific adjustment required for hepatic impairment. Use with caution in severe liver disease due to risk of fluid overload.
No specific adjustments required for hepatic impairment. Monitor fluid and electrolyte balance due to potential volume expansion.
For reduction of intracranial pressure: 0.25-1 g/kg (1.25-5 m L/kg of 20% solution) intravenously over 30-60 minutes, repeated every 6-8 hours as needed. Maximum dose: 2 g/kg/day.
0.25-1 g/kg (2.5-10 m L/kg of 10% solution) intravenously over 30-60 minutes, repeated as needed. Max dose 2 g/kg/day. Adjust based on response and serum osmolality.
Start at lower end of dosing range (0.5 g/kg) due to increased risk of renal impairment and hypovolemia. Monitor serum electrolytes, osmolality, and renal function closely. Avoid in patients with significant cardiovascular disease.
Use lower initial doses and monitor renal function and electrolytes closely due to age-related decline in renal function and higher risk of volume overload. Start at 25-50 g (250-500 m L of 10% solution) and titrate.
No FDA boxed warning.
None.
Risk of pulmonary edema or congestive heart failure due to volume expansion,May cause electrolyte imbalance (e.g., hyponatremia, hyperkalemia) and dehydration,Monitor renal function; contraindicated in anuria or severe renal impairment,May increase intracranial pressure rebound effect,Use with caution in patients with severe hypovolemia or electrolyte disorders,Intravenous administration requires careful monitoring of fluid and electrolyte status
Monitor serum electrolytes, osmolality, and renal function during therapy,May cause fluid and electrolyte imbalances, including hyponatremia or hypernatremia,Administer cautiously in patients with renal impairment, heart failure, or pulmonary edema,Use with caution in conditions where increased intravascular volume may be harmful,Do not administer if solution contains particulate matter or is discolored
Anuria due to severe renal disease,Severe pulmonary congestion or pulmonary edema,Severe dehydration,Intracranial hemorrhage (unless during craniotomy) or active intracranial bleeding,Hypersensitivity to mannitol or any component of the formulation
Anuria due to severe renal disease,Severe dehydration,Intracranial hemorrhage (unless during craniotomy),Active intracranial bleeding except during craniotomy,Hypersensitivity to mannitol or dextrose,Congestive heart failure,Pulmonary edema
No significant food interactions. However, patients on this therapy often have restricted fluid and electrolyte intake; follow prescribed dietary restrictions, especially regarding sodium and fluid intake, as directed by the healthcare team.
No clinically relevant food interactions.
Osmitrol 20% is a hyperosmolar agent used for osmotic diuresis. Based on animal studies and human data, mannitol crosses the placenta. In the first trimester, there is a theoretical risk of fetal osmotic shifts, but no well-controlled studies exist. In the second and third trimesters, use may cause fetal dehydration and electrolyte disturbances. Due to its limited indications in pregnancy (e.g., for elevated intracranial pressure), the risk-benefit must be carefully evaluated. Mannitol is assigned to FDA Pregnancy Category C.
No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. First trimester: theoretical risk only, no reported malformations. Second/third trimesters: monitor for maternal hyperosmolality and fluid shifts which may affect fetal hydration status.
It is unknown if mannitol is excreted in human milk. Given its high molecular weight and low lipid solubility, excretion is likely minimal but not confirmed. Caution is advised; use only if clearly needed. M/P ratio is not available.
Not known if mannitol or dextrose are excreted in breast milk. Consider risk of osmotic diarrhea in neonate if present in milk. M/P ratio not established.
Pharmacokinetic changes in pregnancy (increased plasma volume, increased renal clearance) may require dose adjustments. However, mannitol dosing is titrated to effect (e.g., urine output, serum osmolality). Pregnancy may reduce the duration of action. Monitor clinical response more frequently and adjust dose as needed to maintain desired osmolality and avoid toxicity.
No specific dose adjustment recommended; monitor maternal fluid status closely as pregnancy increases risk of pulmonary edema; adjust rate based on urine output and osmolality.
Monitor serum osmolarity and sodium levels closely; risk of hypematremia and hyperosmolality, especially in renal impairment. Use with caution in patients with congestive heart failure or pulmonary congestion. Administer via central line to avoid phlebitis. In acute renal failure, a test dose of 0.2 g/kg over 3-5 minutes may be given; if urine flow increases > 40 m L/h, full therapy can be initiated. Taper abruptly to avoid rebound intracranial hypertension. Contraindicated in anuria, intracranial hemorrhage, severe dehydration, and glucose intolerance (use with caution in diabetics).
Monitor serum sodium and osmolality closely; risk of hypernatremia and acute kidney injury. Use an in-line filter to prevent crystallization. Administer by slow IV infusion to avoid fluid overload. Contraindicated in anuria and severe pulmonary edema.
This medication may cause you to urinate frequently; it is used to reduce brain swelling or to promote urine output.,You may experience headache, nausea, blurred vision, or thirst; report these to your healthcare provider.,Your fluid intake and output, as well as blood tests (electrolytes, kidney function), will be monitored closely.,Do not stop taking this medication abruptly without consulting your doctor; sudden withdrawal may worsen your condition.,Inform your doctor if you have heart disease, kidney disease, or diabetes.,This medication is given intravenously, usually in a hospital setting.
Report any signs of fluid overload like shortness of breath or swelling.,This medicine may cause increased urination and thirst.,Do not take this medication by mouth; it is for intravenous use only.,Inform your healthcare provider if you have kidney problems or heart failure.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 20% IN WATER vs MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, answered by our medical review team.
OSMITROL 20% IN WATER is a Osmotic Diuretic that works by Osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into extracellular fluid and increasing renal tubular osmotic pressure, which inhibits water reabsorption and promotes diuresis.. MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 20% IN WATER and MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 20% IN WATER is: 1-2 g/kg (5-10 m L/kg of 20% solution) intravenously over 30-60 minutes for reduction of intracranial pressure; may repeat every 6-8 hours. For preoperative bowel preparation, 100-200 m L (20% solution) orally.. The standard adult dose of MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is: Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 20% IN WATER and MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 20% IN WATER is classified as Category C. Osmitrol 20% is a hyperosmolar agent used for osmotic diuresis. Based on animal studies and human data, mannitol crosses the placenta. In the first trimester, there is a theoretica. MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is classified as Category A/B. No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. F. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.